Previous 10 | Next 10 |
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that its second-quarter 2019 financial results will be released on Wednesday, Aug. 7, 2019. Following the announcement, Horizon's management will host a live webcast at 8 a.m. Eastern Time to review the Company's financial and operating ...
Horizon Therapeutics (NASDAQ: HZNP ) has priced its $600M 5.5% senior notes due 2027. More news on: Horizon Therapeutics Public Limited Company, Healthcare stocks news, Read more ...
Horizon Therapeutics plc (Nasdaq: HZNP) (“Horizon”) today announced that Horizon Pharma USA, Inc., its wholly-owned subsidiary, has priced its offering of $600 million aggregate principal amount of 5.5% senior notes due 2027. The note offering is expected to close on July 16, 20...
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that Horizon Pharma USA, Inc., its wholly-owned subsidiary, intends, subject to market and other considerations, to offer $500 million aggregate principal amount of senior notes due 2027. Horizon currently expects to use the net proc...
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for its investigational medicine teprotumumab for the treatment of active thyroid eye disease (TED). Teprotumumab has Breakthrough...
- Initiative coincides with Graves’ Disease Awareness Month and the launch of oneGRAVESvoice.com, a new online resource from the Graves’ Disease and Thyroid Foundation for patients, caregivers and physicians – Today marks the launch of a new patient empowerment a...
- Approach informed by regulatory guidance and real-world clinical experience - Horizon Therapeutics plc (Nasdaq: HZNP) today announced the initiation of a clinical trial evaluating KRYSTEXXA® (pegloticase injection) in combination with methotrexate as a strategy to increase the d...
- Poster presentations raise critical systemic correlations central to optimizing patient care - - Oral presentation illustrates novel monitoring tool designed to track response to treatment - Horizon Therapeutics plc (Nasdaq: HZNP) is elevating the dialogue on gout within the ...
Horizon Therapeutics plc (Nasdaq: HZNP), today announced that the company will participate in the following conference in June: The JMP Securities Life Sciences Conference Date: June 20, 2019 Presentation Time: 10 a.m. ET Location: New York The conference presenta...
Aimed at identifying suitable patients for RAVICTI (glycerol phenylbutyrate) Oral Liquid, Horizon Therapeutics ( HZNP -2.3% ) launches a free-of-charge urea cycle disorder (UCD) genetic testing program with Invitae ( NVTA -2% ). More news on: Horizon Therapeutics Public Limited Compa...
News, Short Squeeze, Breakout and More Instantly...
Horizon Therapeutics Public Limited Company Company Name:
HZNP Stock Symbol:
NASDAQ Market:
Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...
Horizon Therapeutics Public Limited Company (HZNP) is expected to report $1.22 for Q3 2023
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE October 6, 2023 RECOM...